THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q1 2020 13F Holders as of 31 Mar 2020

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
93.13%
Total 13F principal
$235,967,348
Principal change
+$2,076,877
Total reported market value
$221,284,490
Number of holders
30
Value change
-$1,394,947
Number of buys
15
Number of sells
11

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q1 2020

As of 31 Mar 2020, THERAVANCE INC - CORPORATE OBLIG was held by 30 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $235,967,348 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, ADVENT CAPITAL MANAGEMENT /DE/, LAZARD ASSET MANAGEMENT LLC, CNH PARTNERS LLC, BNP PARIBAS ARBITRAGE, SA, DeepCurrents Investment Group LLC, Shaolin Capital Management LLC, Polar Asset Management Partners Inc., BANK OF AMERICA CORP /DE/, and NEW YORK STATE COMMON RETIREMENT FUND. This page lists 30 institutional bondholders reporting positions for the Q1 2020 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.